| Metric | Value (₹ Cr) | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue | 1.2K | 0.1% | 9.7% |
| Total Income | 1.2K | 0.1% | 11.2% |
| Expenditure | 1.1K | 0.6% | 6.4% |
| PBT | 121.22 | 21.7% | 61.3% |
| Net Profit | 81.34 | 20.2% | 45.6% |
| OPM | 12.95% | 1.86pp | 3.27pp |
| NPM | 6.82% | 1.15pp | 7.12pp |
| EPS | 5.53 | 27.7% | 42.6% |
Akums FY26: Revenue ₹4,359 Cr, PAT ₹276 Cr; Dividend Announced
14 May 2026 · 14 May, 4:42 pm
Summary
Akums Drugs & Pharmaceuticals Ltd. delivered a strong performance for Q4 FY26 and the full financial year ended March 31, 2026. For Q4 FY26, operating revenue grew by 9.7% year-on-year to ₹1,158 crore, with Adjusted EBITDA surging 61.6% to ₹152 crore, improving the margin to 13.1%. Profit After Tax (Adj PAT) showed exceptional growth of 135% year-on-year, reaching ₹83 crore, with a margin of 7.0%. For the full year FY26, the company recorded operating revenue of ₹4,359 crore, a 5.9% increase, and Adj PAT grew 27.3% to ₹276 crore. Management highlighted the strong domestic CDMO business performance, strategic international developments, and regulatory achievements as key drivers for this steady progress and focus on long-term capabilities.
Key Highlights
- 1
Akums Drugs & Pharmaceuticals Ltd. reported a healthy Q4 FY26 operating revenue of ₹1,158 crore, marking a 9.7% year-on-year growth compared to Q4 FY25.
- 2
Adjusted EBITDA for Q4 FY26 surged by 61.6% year-on-year to ₹152 crore, with the Adjusted EBITDA margin significantly improving to 13.1% from 8.9% in Q4 FY25.
- 3
Profit After Tax (Adj PAT) for Q4 FY26 saw a substantial 135% year-on-year growth, reaching ₹83 crore, with the Adj PAT margin expanding to 7.0% from 3.3%.
- 4
For the full year FY26, operating revenue stood at ₹4,359 crore, reflecting a 5.9% year-on-year growth, while Adj EBITDA increased 13.3% year-on-year to ₹522 crore.
- 5
Full year FY26 Adj PAT grew by 27.3% year-on-year to ₹276 crore.
- 6
The company achieved significant international and regulatory milestones in FY26, including its first commercial supply to Europe, EU GMP certifications, UK MHRA approval for Rivaroxaban, Brazil ANVISA for its injectable plant, and the ground-breaking of a pharmaceutical plant in Zambia.
- 7
The Board recommended a final dividend of INR 1 per equity share and a special dividend of INR 2 per equity share for the year FY25-26.
Management Comments
Mr. Sanjeev Jain
FY26 has been a year of steady progress for Akums. We delivered healthy growth in revenue and profitability while continuing to build capabilities for the long term. Our regulatory milestones, international developments and strong domestic performance reflect our focus on building Akums as a global pharmaceutical company and a trusted partner for our clients.
Mr. Sandeep Jain
The Q4FY26 and full year performance showed improvement across key operational parameters. Our CDMO business continued to perform well as we remain focused on better capacity utilisation, cost discipline and future growth. We are working on multiple digitization and automation initiatives which will deliver long-term value for the organization.
Informational and educational content only. Not investment advice.